<DOC>
	<DOCNO>NCT02168777</DOCNO>
	<brief_summary>Phase I : Determine maximum tolerate dose combination Regorafenib Refamentinib dose escalation study , tumor type meet certain inclusion/exclusion criterion enter . After recommend dose determine , Phase II portion study evaluate tolerability efficacy combination treatment patient breast cancer , lung cancer , colorectal cancer , respectively .</brief_summary>
	<brief_title>Refametinib ( BAY86-9766 ) Combination With Regorafenib ( Stivarga , BAY73-4506 ) Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>Number treatment-emergent Adverse Events ( AEs ) report Adverse Events section . Study originally design Phase I Phase II part , sponsor decide conduct Phase 2 part due strategic portfolio re-prioritization .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Criteria Phase 1b : Patients locally advance metastatic solid tumor either relapse following , progress , standard therapy ; current disease state standard effective therapy ; candidate , unwilling undergo , standard therapy case curative option exists . Cohortspecific criterion Phase 2 : CRC ( Colorectal cancer ) : Patients metastatic CRC know KRAS ( Kirsten rat sarcoma viral oncogene homolog ) status eligible treatment regorafenib accordance approve label . NSCLC ( Nonsmallcell lung cancer ) : Patients NSCLC know KRAS status platinum base chemotherapy . Breast cancer : Patients Her2 negative breast cancer anthracycline taxane base chemotherapy . Baseline tumor tissue conduct molecular / genetic study available study patient enrol study . ( optional Phase 1b ) Patients must least one unidimensional measurable lesion CT MRI accord RECIST version 1.1 . ( applicable Phase 2 ) Male female patient â‰¥ 18 year age ( female patient breast cancer cohort Phase 2 ) . ECOG Performance Status 0 1 Life expectancy least 3 month Adequate bone marrow , liver renal function Cardiac function within normal range Prior treatment refametinib regorafenib . Metastatic brain meningeal tumor Uncontrolled hypertension despite optimal medical management History cardiac disease Arterial venous thrombotic embolic event Any hemorrhage bleeding event History current evidence retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) . Any condition unstable could jeopardize safety patient his/her compliance study . Excluded previous therapy medication : Radiotherapy within 3 week prior start treatment Systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy , hormonal therapy trial within 28 day 5 drug halflives ( drug halflife patient know ) , whichever short ( within 6 week mitomycin C ) start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Patients Cancer</keyword>
</DOC>